secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALX ONCOLOGY HOLDINGS INC (ALXO)
CIK:        0001810182
Form:       8-K
Filed at:   2026-01-30T23:59:59+00:00
Accession:  0001193125-26-030579
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ALX Oncology prices ~$150M equity offering at $1.57/share; includes pre-funded warrants
--------------------------------------------------------------------------------

- Gross proceeds expected ~$150M from sale of 76,979,112 common shares at $1.57 and pre-funded warrants for 18,574,120 shares at $1.569.
- Offering led by new investors RA Capital Management and TCGX, with participation from existing investors.
- Net proceeds to fund evorpacept and ALX2004 clinical trials, working capital.
- Expected close on or about Feb 2, 2026, subject to customary conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810182/000119312526030579/0001193125-26-030579-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810182/000119312526030579/d12882d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-030579

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer